Literature DB >> 4158450

Observations on antigamma globulin factors in human sera and antibodies against autologous gamma globulins produced in rabbits.

R C Williams, H G Kunkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 4158450     DOI： 10.1111/j.1749-6632.1965.tb19008.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

1.  Occurrence of antigammaglobulins in effusion fluids of diverse aetiology.

Authors:  L P Parker; C W Seward; C K Osterland
Journal:  Ann Rheum Dis       Date:  1974-05       Impact factor: 19.103

2.  Phagocytosis in subacute bacterial endocarditis. Localization of the primary opsonic site to Fc fragment.

Authors:  P G Quie; R P Messner; R C Williams
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

3.  FII haemagglutination test for serum antigammaglobulin factors in arthritides sero-positive and sero-negative by other tests.

Authors:  D W Zutshi; C A Reading; W V Epstein; B M Ansell; E J Holborow
Journal:  Ann Rheum Dis       Date:  1969-05       Impact factor: 19.103

4.  Experimentally produced antibodies to the pepsin site of IgG due to untreated autologous IgG in immune complexes.

Authors:  O J Mellbye; J B Natvig
Journal:  Clin Exp Immunol       Date:  1970-08       Impact factor: 4.330

5.  Interactions between rheumatoid factor and native gamma-G-globulins studied in the ultracentrifuge.

Authors:  D E Normansell; D R Stanworth
Journal:  Immunology       Date:  1968-10       Impact factor: 7.397

6.  Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.

Authors:  J E Persselin; R H Stevens
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Serum opsonin, bacteria, and polymorphonuclear leukocyte interactions in subacute bacterial endocarditis. Anti-gamma-globulin factors and their interaction with specific opsonins.

Authors:  R P Messner; T Laxidal; P G Quie; R C Williams
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

8.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.